콘텐츠로 건너뛰기
Merck

HPLC Analysis of Furosemide (Lasix) in Horse Serum on Discovery® C18 after SPE using Discovery® DSC-18

HPLC Analysis of Furosemide (Lasix) in Horse Serum on Discovery® C18 after SPE using Discovery® DSC-18 application for SPE, application for HPLC

Materials

분석 컬럼

제품 번호
설명
가격

Discovery® C18 HPLC Column

5 μm particle size, L × I.D. 15 cm × 4.6 mm

CONDITIONS

sample preparation

SPE (Solid Phase Extraction)

sample/matrix

acidified horse serum spiked with indapamide at 10 mg/mL

SPE tube/cartridge

Discovery DSC-18, 50 mg/1 mL (52601-U)

condition

1 mL methanol; 1 mL 10 mM potassium phosphate, pH 3

sample addition

1 mL

washing

10 mM potassium phosphate, pH 3

elution

1 mL 60% methanol in DI water.

column

Discovery C18, 15 cm x 4.6 mm I.D., 5 μm particles (504955)

mobile phase

[A] 10 mM KH2PO4, pH 3 (adjusted with H3PO4): [B] acetonitrile; (60:40, A:B)

flow rate

1 mL/min

column temp.

35 °C

detector

UV, 234 nm

injection

10 μL

설명

애플리케이션

Sample Pre-treatment:
Neat horse serum was acidified with 10 mL 6 M HCl/mL serum. Internal standard (I.S.) blank was prepared by spiking acidified horse serum with indapamide at 10 mg/mL. Sample A = 10 mg/mL furosemide in I.S. blank. Sample B = 5 mg/mL furosemide in I.S. blank. Sample C = 0.5 mg/mL furosemide in I.S. blank. Sample D = 0.1 mg/mL furosemide in I.S. blank. Sample E = 0.05 mg/mL furosemide in I.S. blank.

법적 정보

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany